Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2020 Sep 17;15(9):e0239642. doi: 10.1371/journal.pone.0239642

Correction: Improved residual fat malabsorption and growth in children with cystic fibrosis treated with a novel oral structured lipid supplement: A randomized controlled trial

Virginia A Stallings, Alyssa M Tindall, Maria R Mascarenhas, Asim Maqbool, Joan I Schall
PMCID: PMC7498082  PMID: 32941528

The Competing Interests statement is incorrect. The correct Competing Interests statement is as follows: LXS (now known as Encala™) was a product of BioMolecular Products, Inc and was used for the clinical trial. Envara Health was founded in 2018 to develop therapeutic nutrition products related to the licensed LXS (now Encala™) technology. After study completion, VAS co-founded Envara Health and serves as a consultant.

Reference

  • 1.Stallings VA, Tindall AM, Mascarenhas MR, Maqbool A, Schall JI (2020) Improved residual fat malabsorption and growth in children with cystic fibrosis treated with a novel oral structured lipid supplement: A randomized controlled trial. PLoS ONE 15(5): e0232685 10.1371/journal.pone.0232685 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from PLoS ONE are provided here courtesy of PLOS

RESOURCES